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osteoarthritis?







Osteoarthritis was long viewed as a degenerative joint dis-
ease characterized by gradual cartilage attrition. Mechanical factors
were very often incriminated and patient management limited
to pain control. Subsequently, osteoarthritis was  deﬁned as a
family of diseases involving all the articular and periarticular
tissues, including the muscles and tendons [1]. The role for syn-
ovitis and subchondral-bone sclerosis has been ﬁrmly established.
Research focused on the joint tissues and documented changes
in the metabolic activity and phenotype of chondrocytes, syn-
oviocytes, and subchondral-bone osteoblasts. Several signaling
pathways have been incriminated in these changes. Examples
include the nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-B) pathway, whose activation by numerous
cytokines (e.g., IL-1) and growth factors upregulates the expres-
sion of many genes involved in connective tissue inﬂammation and
breakdown; and the NF-B/HIF-2 pathway, which plays a role in
endochondral ossiﬁcation. Activation of the B/HIF-2 pathway
by mechanical factors or proinﬂammatory cytokines stimulates
production by the chondrocytes of osteogenic factors, matrix met-
alloproteinase (MMP)-13, and collagen type X [2]. Another relevant
pathway is JAKs/STATs, which ensures rapid signal transduction
between membrane receptors and target genes. Janus kinases
(JAKs) are involved in activating phosphorylation via the tran-
scription factors signal transducers and activators of transcription
(STATs), which migrate to the nucleus, where they bind to DNA
sequences within target gene promoters. The JAKs/STATs pathway
is activated by numerous cytokines such as IL-6. JAKs/STATs acti-
vation induces the expression of genes encoding proinﬂammatory
cytokines and MMPs  directly involved in cartilage breakdown and
synovial membrane inﬂammation [3]. Activation of the Insulin/IGF-
1/Pl3k/Akt/forkhead-box class O (FoxO) pathway is related to
chondrocyte aging. FoxO factors play a central role in cell resis-
tance to oxidative stress [4] and their inhibition results in decreased
antioxidant production. The Wnt  pathway is also a focus of active
research. Its role is complex. Wnt  pathway activation and inhibition
induce osteoarthritis in experimental animals [5]. These pathways
constitute potential treatment targets.
More recently, osteoarthritis has been described as a metabolic
disease, based on evidence of a correlation between clinical hand
osteoarthritis severity and obesity [6]. Obesity does not increase the
mechanical loads on the hands, and a systemic effect of obesity on
hand osteoarthritis has therefore been suggested [7]. Adipose tissue
releases proinﬂammatory cytokines (e.g., tumor necrosis factor-,
IL-6) and adipokines (e.g., leptin, adiponectin, and visfatin), which
exert deleterious effects on joint tissues (Fig. 1) [8]. Studies of
patients with obesity have shown associations linking osteoarthri-
tis to the metabolic syndrome and its components (hypertension,
dyslipidemia, and type 2 diabetes). Furthermore, associations have
been reported between knee osteoarthritis and metabolic syn-
drome components such as type 2 diabetes and hypertension,
independently from the presence of obesity or other known risk
factors for osteoarthritis [9]. Finally, the accumulation of metabolic
risk factors such as overweight, hypertension, dyslipidemia, and
hyperglycemia increases the risk of knee osteoarthritis develop-
ment and progression [10]. The link between metabolic syndrome
and osteoarthritis may  be chronic low-grade systemic inﬂamma-
tion characterized by elevated circulating levels of reactive oxygen
species, oxidized low-density lipoproteins (LDLs), lipid mediators,
or adipokines.
These recent data have changed the manner in which both
patients and healthcare professionals view osteoarthritis. Clini-
cians and researchers are now seeking to classify patients with
osteoarthritis based on the disease phenotype. Potential cate-
gories include metabolic osteoarthritis, early genetic osteoarthri-
tis, age-related osteoarthritis, and posttraumatic osteoarthritis.
Phenotype-based classiﬁcation will result in management strate-
gies tailored to the disease characteristics, thereby increasing the
response rates to each treatment.
The therapeutic objective in patients with osteoarthritis is to
control the symptoms via a combination of pharmacological and
nonpharmacological treatments [11]. The main nonpharmacolog-
ical treatments are weight loss and physical exercise designed to
maintain muscle function and to decrease body fat. Nonsteroidal
anti-inﬂammatory drugs and paracetamol are the most widely used
drugs but carry a high risk of severe side effects that limits their use
in patients with osteoarthritis and comorbidities.
In contrast to patients with rheumatoid arthritis (RA), those
with osteoarthritis have not yet beneﬁted from treatment break-
throughs capable of signiﬁcantly slowing disease progression.
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Fig. 1. Pathophysiology of osteoarthritis (OA) associated with obesity. MCP-1: monocyte chemotactic protein-1; SAA: serum amyloid A; IL-1: interleukin-1 beta; TNF-
:  tumor necrosis factor alpha; IL-6: interleukin-6. Since a relationship was demonstrated between hand osteoathritis and obesity, obesity-related OA is considered as a
metabolic diseases involving systemic between the two  conditions through the release of proinﬂammatory cytokines but also adipokines likes leptin, adiponect ot visfatin
which can directly activate chondrocytes like mechanical stress or proinﬂammatory cytokines. Obesity also promotes a number of co-morbidities, including the metabolic
syndrome, which may  increase the risk of OA. Finally, OA, particularly age-related OA, is associated to chronic low-grade inﬂammation through the mediator released by
joint  tissues but also by other ageing tissue.
Biotherapies targeting IL-1 or TNF have shown little efﬁcacy in
patients with hand or knee osteoarthritis [12]. In addition, the
severe side effects of these targeted treatments limit the accept-
ability of their long-term use, as they are disproportionate with the
severity of osteoarthritis. Nevertheless, patients with osteoarthri-
tis may  beneﬁt from therapeutic advances achieved in RA, notably
from the development of small molecules that speciﬁcally inhibit
the JAKs. An example is CP-690,550 (tofacitinib). JAK/STAT path-
way inhibition is now a treatment target not only in RA, but also
in osteoarthritis. Tofacitinib inhibits the activity of JAKs 1, 2, and 3,
exhibiting greater afﬁnity for JAK3 than for JAKs 1 and 2. Tofac-
itinib has been evaluated in six phase II studies and six phase
III studies including about 5000 patients with RA [3]. The results
showed signiﬁcant decreases in symptoms and disease activity,
even in patients having failed prior biotherapies [13]. The inci-
dence of side effects (infections and gastric perforation) was similar
to that seen with biotherapies [14]. To our knowledge, tofacitinib
has not yet been evaluated in patients with osteoarthritis. Nev-
ertheless, the results of trials in RA suggest that tofacitinib may
eventually become the ﬁrst speciﬁc signaling pathway inhibitor
for evaluation in patients with osteoarthritis. Finally, the recently
identiﬁed Runx1 inhibitor TD-198946 prevents the development
of cartilage damage in mice with osteoarthritis induced by sur-
gical meniscectomy and section of the median knee ligament
[15].
Signaling pathways hold promise as treatment targets in
osteoarthritis, as their inhibition or activation regulates the expres-
sion of a set of target genes directly involved in joint tissue
metabolic dysfunctions. Nevertheless, the ﬁrst clinical trials in
RA have shown that speciﬁc regulation of the JAK/STAT pathway
induces numerous side effects. Thus, safety concerns may  limit
the use of speciﬁc inhibitors or activators of signaling pathways
in osteoarthritis. The risk/beneﬁt ratio must remain at the center
of treatment decisions, as osteoarthritis is a slowly progressive and
moderately severe disease that is associated with multiple comor-
bidities.
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